A validation study on an in vitro skin irritation assay was performed with the reconstructed human epidermis (RhE) LabCyte EPI-MODEL24, developed by Japan Tissue Engineering Co. Ltd (Gamagori, Japan). The protocol that was followed in the current study was an optimised version of the EpiSkin protocol (LabCyte assay). According to the United Nations Globally Harmonised System (UN GHS) of classification for assessing the skin irritation potential of a chemical, 12 irritants and 13 non-irritants were validated by a minimum of six laboratories from the Japanese Society for Alternatives to Animal Experiments (JSAAE) skin irritation assay validation study management team (VMT). The 25 chemicals were listed in the European Centre for the Validation of Alternative Methods (ECVAM) performance standards. The reconstructed tissues were exposed to the chemicals for 15 minutes and incubated for 42 hours in fresh culture medium. Subsequently, the level of interleukin-1 alpha (IL-1α) present in the conditioned medium was measured, and tissue viability was assessed by using the MTT assay. The results of the MTT assay obtained with the LabCyte EPI-MODEL24 (LabCyte MTT assay) demonstrated high within-laboratory and between-laboratory reproducibility, as well as high accuracy for use as a stand-alone assay to distinguish skin irritants from non-irritants. In addition, the IL-1α release measurements in the LabCyte assay were clearly unnecessary for the success of this model in the classification of chemicals for skin irritation potential.
DraizeJ.H., WoodardG. & CalveryH.O. (1944). Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. Journal of Pharmacology & Experimental Therapeutics82, 377–390.
CannonC.L., NealP.J., SoutheeJ.A., KubilusJ. & KlausnerM. (1994). New epidermal model for dermal irritancy testing. Toxicology in Vitro8, 889–891.
4.
PonecM., BoelsmaE., WeerheimA., MulderA., BouwstraJ. & MommaasM. (2000). Lipid and ultrastructural characterization of reconstructed skin models. International Journal of Pharmaceutics203, 211–225.
5.
ECVAM (2007). Statement on the Validity of In-vitro Tests for Skin Irritation, 7pp. Ispra, Italy: European Commission, Joint Research Centre, Institute for Health and Consumer Protection, European Centre for the Validation of Alternative Methods, Scientific Advisory Committee. Available at: http://iccvam.niehs.nih.gov/methods/dermal/epiderm/ESAC26-SkinIrritation.pdf (Accessed 10. 01.12).
6.
ECVAM (2008). Statement on the Scientific Validity of In-vitro Tests for Skin Irritation Testing, 7pp. Ispra, Italy: European Commission, Joint Research Centre, Institute for Health and Consumer Protection, European Centre for the Validation of Alternative Methods, Scientific Advisory Committee. Available at: http://ecvam.jrc.ec.europa.eu/ (Accessed 10.01.12).
7.
ECVAM (2009). Statement on the Performance Under UN GHS of Three In-vitro Assays for Skin Irritation Testing and the Adaptation of the Reference Chemicals and Defined Accuracy Values of the ECVAM Skin Irritation Performance Standards, 8pp. Ispra, Italy: European Commission, Joint Research Centre, Institute for Health and Consumer Protection, European Centre for the Validation of Alternative Methods, Scientific Advisory Committee. Available at http://ecvam.jrc.ec.europa.eu/ (Accessed 10.01.12).
FentemJ.H., BriggsD., ChesnéC., ElliottG.R., HarbellJ.W., HeylingsJ.R., PortesP., RoguetR., van de SandtJ.J. & BothamP.A. (2001). A prevalidation study on in vitro tests for acute skin irritation. Results and evaluation by the Management Team. Toxicology in Vitro15, 57–93.
10.
PortesP., GrandidierM-H., CohenC. & RoguetR. (2002). Refinement of the Episkin protocol for the assessment of acute skin irritation of chemicals: Follow-up to the ECVAM prevalidation study. Toxicology in Vitro16, 765–770.
11.
ZuangV., BallsM., BothamP.A., CoquetteA., CorsiniE., CurrenR.D., ElliottG.R., FentemJ.H., HeylingsJ.R., LiebschM., MedinaJ., RoguetR., van de SandtJ.J., WiemannC. & WorthA.P. (2002). Follow-up to the ECVAM prevalidation study on in vitro tests for acute skin irritation. The European Centre for the Validation of Alternative Methods Skin Irritation Task Force report 2. ATLA30, 109–129.
12.
KandárováH., LiebschM., GenschowE., GernerI., TraueD., SlawikB. & SpielmannH. (2004). Optimisation of the EpiDerm test protocol for the upcoming ECVAM validation study on in vitro skin irritation tests. ALTEX21, 107–114.
13.
KandárováH., LiebschM., GernerI., SchmidtE., GenschowE., TraueD. & SpielmannH. (2005). The EpiDerm test protocol for the upcoming ECVAM validation study on in vitro skin irritation tests — An assessment of the performance of the optimised test. ATLA33, 351–367.
14.
CotovioJ., GrandidierM-H., PortesP., RoguetR. & RubinstennG. (2005). The in vitro acute skin irritation of chemicals: Optimisation of the EPISKIN prediction model within the framework of the ECVAM validation process. ATLA33, 329–349.
15.
HoffmannS. (2006). ECVAM Skin Irritation Validation Study Phase II: Analysis of the Primary Endpoint MTT and the Secondary Endpoint IL-1α, 190pp. Ispra, Italy: European Commission, Joint Research Centre, Institute for Health and Consumer Protection, European Centre for the Validation of Alternative Methods. Available at: http://ecvam.jrc.it/ft_doc/ATT00042_s.pdf (Accessed 11.01.12).
16.
SpielmannH., HoffmannS., LiebschM., BothamP., FentemJ.H., EskesC., RoguetR., CotovioJ., ColeT., WorthA., HeylingsJ., JonesP., RoblesC., KandárováH., GamerA., RemmeleM., CurrenR., RaabeH., CockshottA., GernerI. & ZuangV. (2007). The ECVAM international validation study on in vitro tests for acute skin irritation: Report on the validity of the EPISKIN and EpiDerm assays and on the Skin Integrity Function Test. ATLA35, 559–601.
17.
EskesC., ColeT., HoffmannS., WorthA., CockshottA., GernerI. & ZuangV. (2007). The ECVAM international validation study on in vitro tests for acute skin irritation: Selection of test chemicals. ATLA35, 603–619.
18.
GriesingerC., BarrosoJ., ZuanV., ColeT., GenschowE. & LiebschM. (2010). Explanatory Background Document to the OECD Draft Test Guideline on In Vitro Skin Irritation Testing, 209pp. Ispra, Italy: European Commission, Joint Research Centre, Institute for Health and Consumer Protection, European Centre for the Validation of Alternative Methods.
19.
ECVAM (2009). ESAC Statement on the Performance Standards (PS) for In Vitro Skin Irritation Testing Using Reconstructed Human Epidermis, 7pp. Ispra, Italy: European Commission, Joint Research Centre, Institute for Health and Consumer Protection, European Centre for the Validation of Alternative Methods, Scientific Advisory Committee. Available at: http://ecvam.jrc.it/publication/ESAC31_statement_updated-skin-irritation-PS_200909-22.pdf (Accessed 20.01.12).
20.
ECH (2010). European Chemicals Agency. Helsinki, Finland: European Chemicals Agency. Available at: http://ec.europa.eu/echa/home_en.html (Accessed 23.01.12).
21.
Anon. (2004). Commission Staff Working Document. Timetables for the Phasing-out of Animal Testing in the Framework of the 7th Amendment to the Cosmetics Directive (Council Directive 76/768/EEC), 8pp. Brussels, Belgium: Commission of the European Communities. Available at: http://ec.europa.eu/consumers/sectors/cosmetics/files/doc/antest/sec_2004_1210_en.pdf (Accessed 23.01.12).
KatohM., HamajimaF., OgasawaraT. & HataK-I. (2009). Assessment of the human epidermal model LabCyte EPI-MODEL for in vitro skin irritation testing according to European Centre for the Validation of Alternative Methods (ECVAM)-validated protocol. Journal of Toxicological Science34, 327–334.
24.
OECD (2005). OECD Series on Testing and Assessment. No. 34. Guidance Document on the Validation and International Acceptance of New or Updated Test Methods for Hazard Assessment, 96pp. Paris, France: Organisation for Economic Co-operation and Development. Available at: http://www.oecd.org/officialdocuments/displaydocumentpdf/?cote=env/jm/mono(2005)14&doclanguage=en (Accessed 16.01.12).
25.
HartungT., BremerS., CasatiS., CoeckeS., CorviR., FortanerS., GribaldoL., HalderM., HoffmannS., RoiA.J., PrietoP., SabbioniE., ScottL., WorthA. & ZuangV. (2004). A modular approach to the ECVAM principles on test validity. ATLA32, 467–472.
26.
RheinwaldJ.G. & GreenH. (1975). Serial cultivation of strains of human epidermal keratinocytes: The formation of keratinizing colonies from single cells. Cell6, 331–344.
27.
GreenH. (1978). Cyclic AMP in relation to proliferation of the epidermal cell: New view. Cell15, 801–811.
ECVAM (2009). ECVAM Skin Irritation Validation Study. Validation of the EpiSkin™ Test Method 15 min–42 hours for the Prediction of Acute Skin Irritation of Chemicals, 43pp. Ispra, Italy: European Commission, Joint Research Centre, Institute for Health and Consumer Protection, European Centre for the Validation of Alternative Methods. Available at: http://ecvam.jrc.it/ft_doc/EPISKIN-SIT-SOP%20JC%20V13-23%2002%2009.pdf (Accessed 20.01.12).
30.
AleI.S. & MaibachH.I. (2008). Mechanisms in irritant and allergic contact dermatitis. In Dermatotoxicology (ed. ZhaiH., WilhelmK-P. & MaibackH.I.), 7th edn, pp. 159–167. Boca Raton, FL, USA: CRC Press.
31.
CoquetteA., BernaN., VandenboschA., RosdyM., De WeverB. & PoumayY. (2003). Analysis of interleukin-1alpha (IL-1alpha) and interleukin-8 (IL-8) expression and release in in vitro reconstructed human epidermis for the prediction of in vivo skin irritation and/or sensitization. Toxicology in Vitro17, 311–321.
